ClinicalTrials.gg
Status unknownNCT03477929IVFUpdated Mar 27, 2018

Cetrorelix and Ganirelix Flexible Protocol for (IVF)

A Phase 4 interventional study of Ganirelix Acetate and Cetrorelix Acetate in Infertility/Sterility, sponsored by Università degli Studi 'G. d'Annunzio' Chieti e Pescara. Status unknown at 1 site in Italy. Open to female participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-27.

Sponsored by Università degli Studi 'G. d'Annunzio' Chieti e Pescara · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2017, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 39 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies testing cetrorelix in Infertility — 1 open to participants now, 1 under way, none of them phase 3. cetrorelix · Infertility.

Planned enrollment
8th of 17
100 · median 99
Started
2017
with 1 other
Phase 4
10 of 17
none open now
Registered
11th of 17
by date

Among the 17 studies testing cetrorelix in Infertility, this one is the 8th largest by planned enrollment, is one of 2 that started in 2017, is one of 10 in phase 4, and was the 11th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 356 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 17 studies testing cetrorelix in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About cetrorelix

cetrorelix: first FDA approval 2000 (CETROTIDE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 39 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing cetrorelix in Infertility, or all of them as a file.
02

Study summary

Recombinant gonadotropins are currently used for ovarian stimulation in women undergoing to IVF for infertility. Recently new flexible protocols have been introduced: the "single dose" and "multiple dose" protocol. The single dose protocol is performed just using Cetrorelix by the administration of a single injection of Cetrorelix 3 mg subcutaneous when the lead follicle is ≥ 14 mm. The multiple dose protocol consider the daily administration of Cetrorelix 0.25 mg subcutaneous or Ganirelix 0.25 mg subcutaneous when the lead follicle is ≥ 14 mm and until the realization of hCG criteriaThere are few data from letterature about the comparison of the efficacy in pitituary suppression and pregnancy outcome of Ganirelix and Cetrorelix.

Objective: to compare the efficacy in pituitary gonadotropin suppression and IVF outcome of multiple dose flexible gonadotrophin-releasing hormone (GnRH) antagonist administration according to follicular size using daily injection of Cetrorelix or Ganirelix.

Interventions : patients are randomly assigned in to Cetrorelix acetate group or Ganirelix acetate group. Multiple dose of Cetrorelix acetate (0.25 mg) or multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met.Oocyte maturation trigger is performed by the administration of subcutaneous r-hCG (250 μg) or of intramuscular hCG (10,000 IU). After 36 hour transvaginal oocyte retrieval is performed followed by ICSI and embrio transfer (72 hours later).

03

Conditions studied

  • Infertility/Sterility

Browse trials for

Keywords

  • In vitro fertilization
  • gnrh antagonist
  • pituitary suppression
04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-39 hyears old with regular menstrual cycles (25-35 days in length);
  • between 18-29 kg\m2
  • Basal follicle-stimulating hormone levels within normal range (\<30 mUI\mL)
  • Absence of anomalies at transvaginal ultrasound examinatio

Exclusion criteria

Exclusion Criteria:

  • Patients affected by grade III or IV endometriosis according to American Society for Reproductive Medicine (ASRM)
  • History of Ovarian Hyperstimulation Stimulation (OHSS)
  • History of poor response in previous IVF\ICSI cycle: ≤ 3 oocytes retrieved
  • ≥ 3 prior consecutive IVF\ICSI cycle without a clinical pregnancy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    ganirelix

    multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met

    Drug: Ganirelix Acetate

  • Experimental
    cetrorelix

    multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met

    Drug: Cetrorelix Acetate

Interventions

  • DrugGanirelixStudies of GanirelixGanirelix pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met

  • DrugCetrorelixStudies of CetrorelixCetrorelix pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met

06

What researchers measure

Primary outcomes

  1. serum LH levels

    percentage of patients not having serum levels of LH ≥ 10IU\\L (defined as premature LH surge) on the day of hCG administration.

    Time frame: through study completion,an average of 9 months

Secondary outcomes

  1. number of follicles ≥ 14mm on the day of hCG administration

    number of follicles ≥ 14mm

    Time frame: through study completion,an average of 9 months

  2. FSH serum levels on the day of hCG administration

    mUI/ml

    Time frame: through study completion,an average of 9 months

  3. FSH on the day of antagonist administration

    mUI/ml

    Time frame: through study completion,an average of 9 months

  4. FSH serum level on the day after the antagonist administration

    mUI/ml

    Time frame: through study completion,an average of 9 months

  5. LH serum level on the day of antagonist administration

    mUI/ml

    Time frame: through study completion,an average of 9 months

  6. LH serum level on the day after the antagonist administration

    mUI/ml

    Time frame: through study completion,an average of 9 months

  7. E2 serum level on the day of antagonist administration

    mUI/ml

    Time frame: through study completion,an average of 9 months

  8. E2 serum level on the day after the antagonist administration

    mUI/ml

    Time frame: through study completion,an average of 9 months

  9. number of oocyte retrieved

    how many oocyte were retrieved on transvaginal oocyte retrieval

    Time frame: through study completion,an average of 9 months

  10. number of metaphase II oocyte retrieved

    how many metaphase II oocyte were retrieved on transvaginal oocyte retrieval

    Time frame: through study completion,an average of 9 months

  11. embryos obtained for patients

    how many embryos were obtained for patient for each arm

    Time frame: 72 hours after transvaginal oocyte retrieval

  12. grade A embryos transferred

    number of grade A embryo were transferred for patient

    Time frame: 72 hours after transvaginal oocyte retrieval

  13. total dose of gonadotropins administered

    number of Units of gonadotropin administered for Controlled Ovarian Hyperstimulation

    Time frame: through study completion,an average of 9 months

  14. duration of gonadotropin treatment

    how many days were necessary to complete the Controlled Ovarian Hyperstimulation

    Time frame: through study completion,an average of 9 months

  15. percentage of patients developing OHSS

    how many patient for each arm develop OHSS (Ovarian Hyperstimulation Syndrome)

    Time frame: 15 days after the transvaginal oocyte retrieval

  16. implantation rate

    The number of gestational sacs observed divided by the number of embryos transferred.

    Time frame: 30 days after the embyo transfer

  17. pregnancy rate

    The number of clinical pregnancy (Positive hCG test) divided by the number of embryos transferred

    Time frame: 14 days after the transvaginal oocyte retrieval

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2017 (actual). Primary completion is estimated for Dec 2018, 13 months after the start.

Of 74 non-industry phase 4 interventional studies under Infertility, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's planned 13 months is below that.

Counting every sponsor, half of 81 studies reached it within 33 months; a quarter within 19 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2018
First posted
Mar 27, 2018
StartActual
Nov 15, 2017
Primary completionEst.
Dec 15, 2018
CompletionEst.
Jan 15, 2019
Last update
Mar 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03477929
Lead sponsor
Università degli Studi 'G. d'Annunzio' Chieti e Pescara
Responsible party
Antonia Iacovelli (Principal Investigator, Università degli Studi 'G. d'Annunzio' Chieti e Pescara) — Principal investigator
First posted
Mar 27, 2018
Start date
Nov 15, 2017
Primary completion
Dec 15, 2018 (estimated)
Completion
Jan 15, 2019 (estimated)
Last update
Mar 27, 2018

Study contacts

Gian Mario Tiboni, professor
Contact
tiboni@unich.it
347 8787545
Antonia Iacovelli, doctor
Contact
antonia.iacovelli.med@gmail.com
3203595229
Gian Mario Tiboni, professor
study director · Università degli Studi 'G. d'Annunzio' Chieti e Pescara

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ganirelix · Cetrorelix

Start the discussion